What is PTCT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PTCT.

Stock Ratings / Health Care / PTCT / options

ERAS (33) TVTX (52) COGT (42) DNTH (39) ⌘ Pro Terminal →

PTC Therapeutics Inc. (PTCT) Options Positioning, Max Pain & Unusual Sweeps

$60.88 +1.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $60.93

PTC Therapeutics Inc. (PTCT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $5.01B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTCT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, PTC Therapeutics Inc. (NASDAQ: PTCT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $60.88 (+1.52% 1D, market cap $5.01B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, PTCT ranks #137 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTCT compare to ERAS and TVTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTCT carries a Roarable C (63/100 RQD), trailing P/E of 7.9x, gross margin of —, and ROIC of 85.0%. By comparison, ERAS (Erasca Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.02B) and TVTX (Travere Therapeutics Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTCT?

▼

Per PTCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070081), PTC Therapeutics Inc. generated $1.73B in revenue (+114.5% YoY), $683.0M in net income, and $702.3M in free cash flow against $2.90B in total assets and $1.40B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $60.93 (+0.08%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 40.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTCT)Realized 20D OHLCV Swing Band: ±8.2%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY PTCT SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (30% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 40.6% FCF Margin ($702.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$59.67+4.9% Next Q

Q2 (-2Q)

Grade C$62.62+0.6% Next Q

Q3 (-1Q)

Grade C$63.02-3.4% Next Q

Current

Grade C$60.88+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PTCT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, PTCT faces multiple-compression risk if 7.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($64.85) or 200D SMA ($70.51) invalidates the momentum regime and cuts Target Base ($62.25) toward Bear Floor ($48.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PTCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PTCT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PTCT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating PTCT & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on PTCT
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PTCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.04%▼ DESCENDING CHANNEL

2026-11-03O $64.46H $64.46L $59.97C $60.88VOL 2.36M

RES: $64.38SUP: $57.14SMA50: $64.85SMA200: $70.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTCT Butterfly Map → + Track PTCT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-5.7%/yr Implied 5Y Growth

vs. +114.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PTCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PTCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTCT)

Health Care Rank #137 of 1015 ⚔️ ERAS vs PTCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTCT vs. ERAS, TVTX, COGT, DNTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PTC Therapeutics Inc. (PTCT) ranks #137 by composite RQD confidence (63/100, grade C) and #163 by equity capitalization ($5.01B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PTCT ACTIVE PTC Therapeutics Inc.	C	63/100	7.9x	—	85.0%	+1.52%	$5.01B	Benchmark Subject
ERAS Erasca Inc.	E	33/100	—	—	-35.0%	-2.09%	$5.02B	/eras-vs-ptct →
TVTX Travere Therapeutics Inc.	D+	52/100	—	96.0%	-13.0%	-2.24%	$4.75B	/tvtx-vs-ptct →
COGT Cogent Biosciences Inc.	D-	42/100	—	—	-35.0%	-4.16%	$5.38B	/cogt-vs-ptct →
DNTH Dianthus Therapeutics Inc.	D-	39/100	—	—	-30.7%	-0.16%	$4.61B	/dnth-vs-ptct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001070081 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PTC Therapeutics Inc. (PTCT) reported GAAP revenue of $1.73B (+114.5% vs. FY2024 revenue of $806.8M , and +84.5% cumulative change since FY2023) , GAAP net income of $683.0M, operating cash flow of $711.2M, and free cash flow of $702.3M (+715.1% YoY). On the balance sheet, PTCT closed FY2025 with $2.90B in total assets against $1.40B in total debt (Altman Z-Score: 1.73, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.73B	$683.0M	$711.2M	$702.3M	$2.90B	$1.40B
FY2024 (FY)	2024-12-31	$806.8M	-$363.3M	-$107.7M	-$114.2M	$1.71B	$285.4M
FY2023 (FY)	2023-12-31	$937.8M	-$626.6M	-$158.4M	-$200.6M	$2.96B	$692.4M

3. PTCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PTCT compare to ERAS and TVTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PTCT?

Where is PTCT trading relative to its 50-day, 200-day, and 52-week technical levels?

PTCT last traded at $60.88 (+1.52% on volume of 1,339,295 shares), positioning the stock -6.12% below its 50-day simple moving average ($64.85) and -13.66% below its 200-day simple moving average ($70.51). Across its 52-week range of $58.80 to $90.87, PTCT sits at the 6.5% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($55.89 to $65.87).

Direct Sub-Reports: PTCT RQD Cockpit PTCT 12M Forecast PTCT Earnings & Move PTCT Dividends & DRIP PTCT Insiders & 13F PTCT Whale Options PTCT Profit Sankey PTCT News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

PTCT — PTC Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PTC Therapeutics Inc. (PTCT) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $60.88 (+1.52% 1D, market capitalization $5.01B).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of —, operating margin of 50.1%, and free cash flow yield of 13.05%.
Whale 13F & Options Flow (5/20) + Insider Conviction (19/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (12/20): Incorporates a 1.15x equity beta, Altman Z-Score of 1.73, Piotroski F-Score of 9/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

PTC Therapeutics Inc. (PTCT) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company as a biotechnology issuer with a market capitalization of $5.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PTC Therapeutics Inc. (PTCT) reported $1.73B in annual revenue (up from $806.8M in FY2024, +114.5% YoY) and $683.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($937.8M revenue, -$626.6M net income) through FY2025, PTCT scaled operating cash flow to $711.2M and free cash flow to $702.3M, backed by $2.90B in total assets against $1.40B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 63/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $58.80 – $90.87 52-week range.
🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 7.9x trailing P/E and 6.5x EV/EBITDA against 50.1% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlation coefficients, or 2nd-order bottlenecks. A prospective investor should note that the reported Q3 loss headline and the record-revenue headline conflict, and that the source does not supply the underlying mechanism; the beta of 1.15 is the only sector-sensitivity figure provided.

Key Question #1: Can PTCT sustain or expand its 50.1% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.73B and free cash flow of $702.3M, how will capital allocation balance growth reinvestment against $1.40B in total debt?
Key Question #3: How sensitive is PTCT's 6.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

PTCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PTC Therapeutics Inc. (PTCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PTCT Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 23h ago

PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss

Yahoo Finance report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

PTC Therapeutics, Inc. Estimates – NASDAQ:PTCT

TradingView report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE FinancialContent • 1d ago

PTC Therapeutics, Inc. - Common Stock (PTCT) Stock Price, News, Quote & History

FinancialContent report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 1d ago

Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q3 Revenue $357.8M

marketscreener.com report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

PTC Therapeutics (PTCT) Reports Record Q3 2026 Revenue, Raises F

GuruFocus report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

PTC Therapeutics Inc (PTCT) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance ...

Yahoo Finance report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $100.33, Implies 56% Upside

TradingView report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In Focus

Yahoo Finance report covering PTC Therapeutics Inc. (PTCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PTCT Bull vs. Bear Conversation Board — What's Your Call at $60.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PTCT 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $70.16 (+17.0%)

📌 Pinned Debate

Reported FY 2025 operating income of $866.9M and an 85% ROIC underpin a 13.05% FCF yield and a 6.6 forward P/E.

The street is overcomplicating PTC Therapeutics Inc. (PTCT). Reported FY 2025 operating income of $866.9M and an 85% ROIC underpin a 13.05% FCF yield and a 6.6 forward P/E.. With an RQD score of 63/100 (C) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $64.77.

EarningsSniper 🐂 BULL

Both sides have a point here — PTCT's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $46.18 (-23.0%)

Spot @ $59.97

A Q3 results-return-to-loss headline, a 1.73 Altman Z-Score, and FY 2025 debt of $1.40B exceeding cash of $984.6M.

I respect the product at PTC Therapeutics Inc., but the stock at $59.97 is a different story. A Q3 results-return-to-loss headline, a 1.73 Altman Z-Score, and FY 2025 debt of $1.40B exceeding cash of $984.6M.. FCF yield is 13.05% and RQD sits at 63/100 (C) — why pay up here when you can wait for next quarter's numbers?